Sonnet BioTherapeutics (SONN) Competitors $1.81 +0.04 (+2.26%) (As of 12/13/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends SONN vs. ADXN, SNGX, GRI, NLSP, EYEN, COEP, OBSV, MBRX, ADIL, and GLTOShould you be buying Sonnet BioTherapeutics stock or one of its competitors? The main competitors of Sonnet BioTherapeutics include Addex Therapeutics (ADXN), Soligenix (SNGX), GRI Bio (GRI), NLS Pharmaceutics (NLSP), Eyenovia (EYEN), Coeptis Therapeutics (COEP), ObsEva (OBSV), Moleculin Biotech (MBRX), Adial Pharmaceuticals (ADIL), and Galecto (GLTO). These companies are all part of the "pharmaceutical products" industry. Sonnet BioTherapeutics vs. Addex Therapeutics Soligenix GRI Bio NLS Pharmaceutics Eyenovia Coeptis Therapeutics ObsEva Moleculin Biotech Adial Pharmaceuticals Galecto Addex Therapeutics (NASDAQ:ADXN) and Sonnet BioTherapeutics (NASDAQ:SONN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, community ranking, valuation and institutional ownership. Which has more risk and volatility, ADXN or SONN? Addex Therapeutics has a beta of 1.74, meaning that its stock price is 74% more volatile than the S&P 500. Comparatively, Sonnet BioTherapeutics has a beta of 0.44, meaning that its stock price is 56% less volatile than the S&P 500. Is ADXN or SONN more profitable? Addex Therapeutics has a net margin of 850.30% compared to Sonnet BioTherapeutics' net margin of 0.00%. Addex Therapeutics' return on equity of -112.43% beat Sonnet BioTherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Addex Therapeutics850.30% -112.43% -77.95% Sonnet BioTherapeutics N/A -398.45%-142.16% Does the MarketBeat Community believe in ADXN or SONN? Sonnet BioTherapeutics received 4 more outperform votes than Addex Therapeutics when rated by MarketBeat users. Likewise, 82.61% of users gave Sonnet BioTherapeutics an outperform vote while only 51.72% of users gave Addex Therapeutics an outperform vote. CompanyUnderperformOutperformAddex TherapeuticsOutperform Votes1551.72% Underperform Votes1448.28% Sonnet BioTherapeuticsOutperform Votes1982.61% Underperform Votes417.39% Which has better valuation & earnings, ADXN or SONN? Addex Therapeutics has higher revenue and earnings than Sonnet BioTherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAddex Therapeutics$556.05K15.25-$11.76M-$0.34-23.53Sonnet BioTherapeutics$55.88K22.12-$18.83MN/AN/A Does the media refer more to ADXN or SONN? In the previous week, Sonnet BioTherapeutics had 5 more articles in the media than Addex Therapeutics. MarketBeat recorded 7 mentions for Sonnet BioTherapeutics and 2 mentions for Addex Therapeutics. Addex Therapeutics' average media sentiment score of 0.96 beat Sonnet BioTherapeutics' score of 0.64 indicating that Addex Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Addex Therapeutics Positive Sonnet BioTherapeutics Positive Do analysts recommend ADXN or SONN? Addex Therapeutics currently has a consensus price target of $30.00, suggesting a potential upside of 275.00%. Sonnet BioTherapeutics has a consensus price target of $30.00, suggesting a potential upside of 1,557.46%. Given Sonnet BioTherapeutics' higher possible upside, analysts plainly believe Sonnet BioTherapeutics is more favorable than Addex Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Addex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Sonnet BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals believe in ADXN or SONN? 16.1% of Addex Therapeutics shares are owned by institutional investors. Comparatively, 9.4% of Sonnet BioTherapeutics shares are owned by institutional investors. 15.0% of Addex Therapeutics shares are owned by insiders. Comparatively, 2.0% of Sonnet BioTherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. SummaryAddex Therapeutics beats Sonnet BioTherapeutics on 9 of the 14 factors compared between the two stocks. Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get Sonnet BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SONN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SONN vs. The Competition Export to ExcelMetricSonnet BioTherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.24M$6.86B$5.28B$9.25BDividend YieldN/A3.04%5.21%4.00%P/E RatioN/A10.59108.7917.54Price / Sales22.12311.511,339.24143.56Price / CashN/A57.2942.3538.50Price / Book-1.765.244.884.88Net Income-$18.83M$151.98M$119.70M$225.52M7 Day Performance-13.81%-5.40%17.72%-0.12%1 Month Performance-39.67%-4.00%20.15%5.71%1 Year Performance16.03%14.38%37.80%21.36% Sonnet BioTherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SONNSonnet BioTherapeutics1.4839 of 5 stars$1.81+2.3%$30.00+1,557.5%+19.1%$1.24M$55,881.000.0012Gap UpADXNAddex Therapeutics3.0037 of 5 stars$7.97-2.2%$30.00+276.4%+34.7%$8.45M$556,045.00-23.6230Short Interest ↓SNGXSoligenix1.6226 of 5 stars$3.36+4.0%N/A-66.9%$8.43M$840,000.000.0020Short Interest ↓GRIGRI Bio1.4946 of 5 stars0.94+18.7%N/A-97.9%$8.38MN/A0.001Short Interest ↓Analyst RevisionGap UpNLSPNLS Pharmaceutics0.4369 of 5 stars$2.16-0.9%N/A+354.5%$8.25MN/A0.006Short Interest ↑News CoverageEYENEyenovia2.0046 of 5 stars$0.10+8.6%$2.00+2,000.8%-95.3%$8.23M$31,832.00-0.1340Short Interest ↑Gap UpHigh Trading VolumeCOEPCoeptis Therapeutics0.7279 of 5 stars$0.20+7.1%N/A-82.0%$8.04M$80,000.000.002Short Interest ↑News CoverageGap UpOBSVObsEvaN/AN/AN/AN/A$7.94M$20.11M-0.1150MBRXMoleculin Biotech3.2572 of 5 stars$2.61-0.8%$31.00+1,087.7%-70.7%$7.83MN/A0.0020Short Interest ↓Gap DownADILAdial Pharmaceuticals3.5203 of 5 stars$1.21+0.8%$8.00+561.2%-39.2%$7.75MN/A0.0020Short Interest ↓Gap UpGLTOGalecto2.4934 of 5 stars$5.71+1.6%$10.00+75.1%-66.7%$7.54MN/A-0.2940Short Interest ↑ Related Companies and Tools Related Companies Addex Therapeutics Competitors Soligenix Competitors GRI Bio Competitors NLS Pharmaceutics Competitors Eyenovia Competitors Coeptis Therapeutics Competitors ObsEva Competitors Moleculin Biotech Competitors Adial Pharmaceuticals Competitors Galecto Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SONN) was last updated on 12/14/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredWaveBot: The Automated Trading Tool for This Bull MarketThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonnet BioTherapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sonnet BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
